SYSTEMATIC REVIEW ON THE COMPARATIVE ANALYSIS OF FACTORS AFFECTING CARDIOVASCULAR DISEASES ASSOCIATED WITH DRUGS.
Main Article Content
Keywords
Cardiovascular diseases, drug interaction, antihypertensives, statins, polypharmacy, risk factors
Abstract
Cardiovascular diseases (CVDs) are among the leading causes of mortality worldwide, with drug interactions playing a significant role in the onset or exacerbation of these conditions. This systematic review provides a comparative analysis of factors influencing CVDs related to pharmacological agents. Key factors such as drug dosage, patient comorbidities, genetic predispositions, and drug mechanisms of action are examined. Findings indicate that polypharmacy, improper dosing, and pre-existing conditions are major contributors to CVD risks. Addressing these factors with personalized medicine approaches may help reduce the cardiovascular burden associated with drug use.
References
2. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-42.
3. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011;343.
4. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2013.
5. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol. 2018;71(13):1474-82.
6. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207.
7. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342.
8. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28.
9. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-16.
10. Nunes JPL. Statin therapy in patients with chronic kidney disease: what evidence do we have? Nephrol Dial Transplant. 2019;34(3):405-11.
11. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-62.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Jharna Sahu
Assistant Professor, Department of Pharmacology, Pt. Jawahar Lal Nehru Medical College, Raipur, Chhattisgarh, India.
Dr Tikam Singh Dhruw
Assistant Professor, Department of Pharmacology, Late Smt. Indira Gandhi Memorial Government Medical College, Kanker, Chhattisgarh, India.
Dr Monika Sahu
Assistant Professor, Department of Pharmacology, Chhattisgarh Institute of Medical Science (CIMS), Bilaspur Chhattisgarh, India. Mobile No- 9713239099.
Dr Ashutosh Kumar
Assistant Professor, Department of Biochemistry, SBDMS Medical College, Korba, Chhattisgarh, India.